Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Replimune Group, Inc. due to a class action complaint alleging breaches of fiduciary duties by the board of directors during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [2]. - It is alleged that the defendants overstated the trial's prospects, leading to materially false and misleading statements about Replimune's business and operations [2]. Group 2: Next Steps for Investors - Long-term stockholders of Replimune are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and the ongoing investigation [3]. - The firm offers a no-cost consultation for investors seeking to understand their legal options [3]. Group 3: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents investors in complex litigation across various courts in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Replimune securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors who purchased Replimune securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial's prospects, which the FDA deemed inadequate [5]. - It is claimed that the defendants knew or should have known about material issues affecting the trial, leading to misleading statements about Replimune's business and operations [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. ("Replimune Group, Inc." or the "Company") (NASDAQ: REPL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Replimune Group, Inc. investors who were adversely affected by alleged securities fraud between November 22, 2024 and July 21, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Replimune Group, Inc. regarding a class action lawsuit due to alleged misleading statements related to the IGNYTE trial, which the FDA deemed inadequate [1]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 22, 2024, to July 21, 2025 [1]. - Allegations include that defendants overstated the IGNYTE trial's prospects and failed to disclose material issues, leading to misleading statements about Replimune's business and operations [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle [2]. Group 3: Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. for alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding the IGNYTE trial's prospects, which were known to be inadequate by the defendants, leading to misleading statements about Replimune's business and operations [2]. - The complaint highlights that the FDA deemed the IGNYTE trial inadequate and not well-controlled, which was not disclosed to investors [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the securities class action is from November 22, 2024, to July 21, 2025 [1]. - Investors who purchased Replimune securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [3]. Group 2: Case Background - The lawsuit alleges that defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate and not well-controlled [5]. - The misleading statements resulted in investors suffering damages when the true details about Replimune's business and operations were revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - A class action securities lawsuit has been filed against Replimune Group, Inc. for alleged securities fraud affecting investors between November 22, 2024, and July 21, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding the IGNYTE trial's prospects, which were known to be materially inadequate by the defendants [2] - The FDA deemed the IGNYTE trial inadequate and not well-controlled, leading to misleading statements about Replimune's business and operations [2] Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation does not require this role [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4]

Core Viewpoint - A class action lawsuit has been filed against Replimune Group, Inc. for allegedly making false and misleading statements regarding the IGNYTE trial, which led to investor losses during the specified class period from November 22, 2024, to July 21, 2025 [2][4]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court District of Massachusetts on behalf of all individuals and entities who purchased Replimune securities during the class period [2]. - Investors have until September 22, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. - The lawsuit claims that defendants overstated the IGNYTE trial's prospects, resulting in the FDA deeming the trial inadequate and not well-controlled [4]. Group 2: Investor Information - Investors who suffered losses and are long-term stockholders are encouraged to contact the law firm for more information regarding their rights and potential claims [5]. - The law firm, Bragar Eagel & Squire, P.C., specializes in representing individual and institutional investors in complex litigation [6].

Core Points - Rosen Law Firm is reminding investors who purchased Replimune Group, Inc. securities between November 22, 2024, and July 21, 2025, of the September 22, 2025, lead plaintiff deadline in a securities class action lawsuit [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the firm [3] Case Details - The lawsuit alleges that Replimune's defendants made materially false and misleading statements regarding the IGNYTE trial, which the FDA deemed inadequate [5] - The claims suggest that the defendants overstated the trial's prospects, leading to investor damages when the true information was revealed [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4] - The Rosen Law Firm has a history of significant recoveries for investors, including over $438 million in 2019 alone [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Replimune Group, Inc. regarding a class action lawsuit due to alleged misleading statements related to the IGNYTE trial [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from November 22, 2024, to July 21, 2025 [1]. - The complaint claims that defendants overstated the IGNYTE trial's prospects, leading to the FDA deeming the trial inadequate [1]. - It is alleged that the defendants' statements about Replimune's business and operations were materially false and misleading [1]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially be appointed as lead plaintiff [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. - Participation in the case incurs no cost or obligation for shareholders [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].